Liver Systems Medicine, or LiSyM, is a multidisciplinary research network funded by the BMBF, in which molecular and cell biologists, clinical researchers, pharmacologists, and experts in mathematical modeling examine the liver in its entirety. In LiSyM-Cancer, 42 partners at 35 academic institutions distributed over 22 locations investigate liver cancer development from pre-existing conditions such as non-alcoholic fatty liver disease (NAFLD) or cirrhosis of the liver aiming at the identification of relevant biomarkers for the early diagnosis and prevention of early liver cancer, such as Hepatocellular Carcinoma (HCC).
Our role in this research network lies in the three-dimensional visualization of healthy and pathological tissue samples with the goal of identifying a novel set of morphometric cellular tissue parameters in NAFLD indicative of disease progression.